In the pharmaceutical domain, the advent of cell & gene therapy marks a wave of innovative treatments, with companies forging new paths and emphasizing patents to introduce enhanced technologies. Strategic investments in deals underscore a commitment to industry progression, positioning key players strategically. Job dynamics reveal a nuanced landscape, showcasing leadership roles at the forefront and reflecting the sector’s adaptability to transformative trends. GlobalData’s cell and gene therapy market research evaluates disease epidemiology, provides a 10-year patient-based forecast across the 8MM, and extends sales forecast extrapolations to an additional seven geographical markets, totaling 15 markets. Buy the report here.
Smarter leaders trust GlobalData
This article presents a quarterly round-up of the latest trends in the pharmaceutical industry regarding cell & gene therapy. It provides an overview of recent developments in cell & gene therapy-related deals, talent acquisition, and patent filings within the pharmaceutical industry.
Diverse applications of cell & gene therapy in pharmaceutical industry
Pharma companies in the field of cell & gene therapy are leveraging new technologies and applications to innovate and improve their businesses. One such technology is the use of injection compositions containing isolated mitochondria, which can be used for the prevention and treatment of mitochondria-related diseases. This composition enhances the stability of mitochondria and prevents the formation of blood clots. Another technology is a gene therapy expression system that alleviates cardiac toxicity. This system allows for the expression of a protein in skeletal muscles while minimizing toxicity in the heart. Additionally, there are dual targeted immune regulating compositions that can modulate the activity of cells to treat autoimmune disorders and cancers. Lastly, there are compositions and methods for enhancing donor oligonucleotide-based gene editing, which can modify the genome of cells at a higher frequency. These patents provide the acquirer with valuable technologies and applications in the field of cell & gene therapy, allowing them to develop safer and more effective treatments for various diseases.
The industry experienced a 43% decline in the number of cell & gene therapy-related patent applications in Q3 2023 compared with the previous quarter. On an annual basis, the number of cell & gene therapy-related patent applications in the pharmaceutical industry witnessed a drop of 53% compared with Q3 2022.
Strategic deal trends in cell & gene therapy in pharmaceutical industry
Pharmaceutical companies are not only focusing on innovation to enhance their patent portfolios but are also making strategic investments in cell & gene therapy. These investments aim to secure lucrative deals with partners and position themselves at the forefront of industry advancements. Some of the recent deals underscore the importance of cell & gene therapy in the pharmaceutical industry.
In Q3 2023, the number of cell & gene therapy-related deals in the pharmaceutical industry declined by 54% compared with Q3 2022. On a quarterly basis, there was 52% drop in the number of deals in Q3 2023 compared with the previous quarter.
Impact on hiring
In terms of new job posting, in Q3 2023, the pharmaceutical industry experienced a 11% drop compared with the previous quarter. On an annual basis, job postings also grew by 28%. Notably, management occupations, with a share of 26%, emerged as the top cell & gene therapy-related job roles within the pharmaceutical industry in Q3 2023, with new job postings drop by 22% quarter-on-quarter. Life, physical, and social science occupations came in second with a share of 18% in Q3 2023, with new job postings dropping by 10% over the previous quarter. The other prominent cell & gene therapy roles include computer and mathematical occupations with a 9% share in Q3 2023, and business and financial operations occupations with a 5% share of new job postings.
Bristol-Myers Squibb, F. Hoffmann-La Roche, Charles River Laboratories International, Astellas Pharma, and Sarepta Therapeutics are among the top companies leading in cell & gene therapy hiring within the pharmaceutical industry.
Countries driving adoption of cell & gene therapy in pharmaceutical industry
The US is the leading country in cell & gene therapy adoption within the pharmaceutical industry, boasting the highest number of cell & gene therapy-related patents, jobs, and deals. Meanwhile, Japan, Belgium, Germany and Australia also maintain significant positions in cell & gene therapy adoption within the pharmaceutical industry.
In conclusion, the pharmaceutical industry's exploration of cell & gene therapy manifests through dynamic shifts in strategic deals, patents, and job trends. As the US takes the lead in global adoption, the landscape is marked by collaborative endeavors, transformative patents, and evolving job opportunities, shaping a future of innovative advancements.
To further understand GlobalData's analysis on cell & gene therapy in the pharmaceutical industry, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData patent analytics tracks patent filings and grants across companies and themes. Proprietary databases on deals and job analytics are used to respectively monitor global deal activity and uncover insights from daily job postings to identify trends, company activities, and industry dynamics across different sectors globally.
